Media headlines about Omeros Corporation (NASDAQ:OMER) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Omeros Corporation earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.9489886775338 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern’s scoring:
- Omeros Corporation (OMER) Given Outperform Rating at Wedbush (americanbankingnews.com)
- Seattle’s third-largest biotech seeks $70 million in stock offering (bizjournals.com)
- OMEROS CORPORATION (NASDAQ:OMER) Files An 8-K Entry into a Material Definitive Agreement (4-traders.com)
- Omeros Corporation (OMER) noted a price change of -8.49% and Apollo Endosurgery, Inc. (APEN) closes with a move … – Stocks Gallery (stocksgallery.com)
- Omeros looks to raise $70M in stock offering to fuel drug development pipeline – GeekWire (geekwire.com)
A number of analysts have recently issued reports on OMER shares. Cowen and Company reaffirmed an “outperform” rating on shares of Omeros Corporation in a research report on Saturday, June 3rd. Maxim Group restated a “buy” rating and issued a $24.00 target price (up from $23.00) on shares of Omeros Corporation in a research note on Tuesday, August 8th. BidaskClub downgraded Omeros Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, June 28th. Wedbush reaffirmed an “outperform” rating and issued a $47.00 price target on shares of Omeros Corporation in a report on Wednesday, May 10th. Finally, Cantor Fitzgerald cut Omeros Corporation from a “buy” rating to a “neutral” rating and dropped their price target for the company from $21.00 to $15.00 in a report on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $32.80.
Shares of Omeros Corporation (NASDAQ:OMER) traded down 2.00% during mid-day trading on Friday, reaching $22.03. 528,048 shares of the company’s stock traded hands. Omeros Corporation has a 52 week low of $7.20 and a 52 week high of $27.09. The firm’s market cap is $987.01 million. The company’s 50 day moving average is $21.52 and its 200-day moving average is $16.64.
Omeros Corporation (NASDAQ:OMER) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.12. The company had revenue of $17.15 million for the quarter, compared to analyst estimates of $14.63 million. During the same quarter in the previous year, the business earned ($0.32) earnings per share. The company’s revenue was up 71.5% on a year-over-year basis. Equities analysts expect that Omeros Corporation will post ($1.40) earnings per share for the current fiscal year.
In other Omeros Corporation news, VP Michael A. Jacobsen sold 24,000 shares of Omeros Corporation stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $21.20, for a total value of $508,800.00. Following the sale, the vice president now directly owns 2,650 shares in the company, valued at approximately $56,180. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Michael A. Jacobsen sold 12,000 shares of Omeros Corporation stock in a transaction on Friday, June 16th. The shares were sold at an average price of $24.95, for a total transaction of $299,400.00. Following the completion of the sale, the vice president now owns 19,500 shares in the company, valued at $486,525. The disclosure for this sale can be found here. 13.60% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Omeros Corporation (OMER) Given News Sentiment Score of 0.22” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.com-unik.info/2017/08/19/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-omeros-corporation-omer-stock-price-updated-updated.html.
Omeros Corporation Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
What are top analysts saying about Omeros Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Omeros Corporation and related companies.